FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Articles|January 1, 2008
Faint-Free Blood Draws
With patients who say that they usually faint when blood is drawn or when given an injection, have them lie down and tell them that they "cannot faint when lying down." Whether for physiological or psychological reasons, patients usually do not faint when this is done.
Advertisement
With patients who say that they usually faint when blood is drawn or when given an injection, have them lie down and tell them that they "cannot faint when lying down." Whether for physiological or psychological reasons, patients usually do not faint when this is done.
-- William J. Sciales, MD
Flushing, NY
More Practical Pointers
Advertisement
Related to this article
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.
A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5